在第一季度暴露于塞马格卢提德后的怀孕结果
Adam Morton1,2, Jinwen He1
1Obstetric Medicine and Endocrinology, Mater Health, Raymond Terrace, South Brisbane, QLD, Australia.
Obstetric medicine
|June 9, 2025
概括
这项研究表明,在怀孕早期暴露于塞马格卢提德并不会增加重大先天性异常风险. 然而,使用塞马格卢提德的生育年龄的妇女应该使用有效的避孕措施,直到有进一步的研究.
科学领域:
- 产科和妇科 产科和妇科
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 塞马格卢提德越来越多地用于2型糖尿病和肥胖症.
- 在怀孕初期对塞马格卢提德安全性的数据有限.
- 了解怀孕后果与第一季度的塞马格卢提德暴露至关重要.
研究的目的:
- 审查在怀孕早期暴露于塞马格卢提德的妇女的怀孕结果.
- 评估在第一季度暴露后出现重大先天性异常的风险.
主要方法:
- 一个产科数据库的回顾性审查.
- 涉及澳大利亚布里斯班的一家三级产科医院.
- 包括13名在第一季度暴露于塞马格卢提德的女性.
主要成果:
- 一个婴儿有显著的心脏异常.
- 这种异常发生在母亲血糖控制非常差,肥胖和高血压的情况下.
- 在该队列中没有报告其他重大先天性异常.
结论:
- 研究结果表明,在第一季度暴露于西马格卢提德时,不会增加重大先天性异常的风险.
- 需要进行更大规模的研究来证实这些结果.
- 使用塞马格卢提德的生育年龄妇女应采取有效的避孕措施.
- 对于患有糖尿病的女性来说,预孕咨询至关重要.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Glucagon-like Receptor Agonists
302
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
302
Pathophysiology of Diabetes
894
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
894
Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
181
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
181


